文献速递泌尿生殖与妇科肿瘤放疗

中高危局限性前列腺癌的中度大分割放疗:随机3期HYPRO试验的健康相关生活质量

Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-17

3期HYPRO试验将820例中危或高危局限性前列腺癌患者随机分配至大分割放疗(19次3.4 Gy)或常规分割放疗(39次2.0 Gy),比较患者报告的生活质量。3年随访时,泌尿症状临床相关恶化发生率两组均为33%,胃肠道症状恶化率大分割组38% vs 常规分割组36%,未能证明大分割在泌尿生殖和胃肠道生活质量方面的非劣效性;其他子量表非劣效性成立。

要点

  • 3年时泌尿症状临床相关恶化发生率两组均为33%,差异0.49%支持常规分割,90%CI -7.20%至8.18%。
  • 胃肠道症状恶化率大分割组38% vs 常规分割组36%,差异2.03%支持常规分割,90%CI -6.18%至10.23%。
  • 未证明大分割在泌尿生殖和胃肠道生活质量方面的非劣效性,其他子量表非劣效性成立。

核心结论

  • 未证明大分割放疗在泌尿生殖和胃肠道生活质量方面非劣效,因此不能排除两种治疗间可能存在相关差异。
  • 大分割放疗在雄激素剥夺治疗相关症状、性活动和性功能方面非劣效性成立。

研究设计与样本

  • 3期随机HYPRO试验,820例中危或高危局限性前列腺癌患者随机分配至大分割放疗(19次3.4 Gy)或常规分割放疗(39次2.0 Gy)。
  • 生活质量采用经验证的欧洲癌症研究与治疗组织生活质量问卷前列腺癌25模块测量,分析泌尿症状、胃肠道症状、雄激素剥夺治疗相关症状、性功能和性活动子量表(评分范围0-100)。
  • 基线变化至少5分视为临床相关;若3年临床相关恶化发生率的平均差异<8.0%,则拒绝大分割放疗对相应子量表的劣效性。
  • 共697例男性符合生活质量分析条件,两组基线特征可比。

主要发现

  • 3年随访时,泌尿症状临床相关恶化发生率两组均为33%(差异0.49%支持常规分割;90%CI -7.20%至8.18%)。
  • 胃肠道症状临床相关恶化在大分割组为38%,常规分割组为36%(差异2.03%支持常规分割;90%CI -6.18%至10.23%)。
  • 未证明大分割放疗在泌尿生殖和胃肠道生活质量方面的非劣效性。
  • 其他所有子量表均证明大分割放疗的非劣效性。

关键数值与推荐

  • 基线变化至少5分视为临床相关。
  • 若3年临床相关恶化发生率的平均差异<8.0%,则拒绝大分割放疗对相应子量表的劣效性。
  • 泌尿症状3年临床相关恶化发生率两组均为33%,差异0.49%支持常规分割(90%CI -7.20%至8.18%)。
  • 胃肠道症状3年临床相关恶化率大分割组38% vs 常规分割组36%,差异2.03%支持常规分割(90%CI -6.18%至10.23%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未证明大分割放疗在泌尿生殖和胃肠道生活质量方面的非劣效性,因此不能排除两种治疗间可能存在相关差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase 3 Hypofractionated Irradiation for Prostate Cancer trial compared hypofractionated radiation therapy with conventionally fractionated radiation therapy in patients with localized prostate cancer. Similar 5-year relapse-free survival rates were achieved in both groups, but noninferiority of hypofractionation was not confirmed for genitourinary and gastrointestinal toxicity. Here, we present the secondary trial endpoint on patient-reported quality of life. METHODS AND MATERIALS: A total of 820 patients with intermediate-risk or high-risk prostate cancer were randomized to hypofractionation (19 fractions of 3.4 Gy) or conventional fractionation (39 fractions of 2.0 Gy). Quality of life was measured using a validated questionnaire, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer 25 module. Subscales (score range, 0-100) on urinary symptoms, gastrointestinal symptoms, symptoms related to androgen deprivation therapy, sexual function, and sexual activity were analyzed. Changes from baseline of at least 5 points were considered clinically relevant. Inferiority of hypofractionation for separate subscales was rejected if the mean difference in the 3-year incidence of clinically relevant deterioration between treatments was <8.0%. RESULTS: A total of 697 men were eligible for this quality-of-life analysis. Baseline characteristics were comparable between both groups. At 3-year follow-up, the incidence of clinically relevant deterioration of urinary symptoms was 33% for both treatments (difference 0.49% in favor of conventional fractionation; 90% confidence interval, -7.20% to 8.18%). Such deterioration of gastrointestinal symptoms was reported in 38% of patients receiving hypofractionation versus 36% of patients receiving conventional fractionation (2.03% in favor of conventional fractionation; 90% confidence interval, -6.18% to 10.23%). Therefore, we could not demonstrate noninferiority of hypofractionation for genitourinary and gastrointestinal quality of life. For all other subscales, noninferiority of hypofractionation was demonstrated. CONCLUSIONS: Noninferiority of the hypofractionated treatment was not demonstrated for genitourinary and gastrointestinal quality of life, and therefore we cannot rule out that relevant differences may exist between both treatments. Noninferiority of hypofractionation was demonstrated for symptoms related to androgen deprivation therapy, sexual activity, and sexual function.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wortel RC, Oomen-de Hoop E, Heemsbergen WD, et al. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 30458234. doi:10.1016/j.ijrobp.2018.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。